Cargando…
Characterization of triple‐negative breast cancer preclinical models provides functional evidence of metastatic progression
Triple‐negative breast cancer (TNBC), an aggressive, metastatic and recurrent breast cancer (BC) subtype, currently suffers from a lack of adequately described spontaneously metastatic preclinical models that faithfully reproduce the clinical scenario. We describe two preclinical spontaneously metas...
Autores principales: | Arroyo‐Crespo, Juan J., Armiñán, Ana, Charbonnier, David, Deladriere, Coralie, Palomino‐Schätzlein, Martina, Lamas‐Domingo, Rubén, Forteza, Jerónimo, Pineda‐Lucena, Antonio, Vicent, María J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767480/ https://www.ncbi.nlm.nih.gov/pubmed/30860605 http://dx.doi.org/10.1002/ijc.32270 |
Ejemplares similares
-
SPARC in cancer‐associated fibroblasts is an independent poor prognostic factor in non‐metastatic triple‐negative breast cancer and exhibits pro‐tumor activity
por: Alcaraz, Lindsay B., et al.
Publicado: (2022) -
Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap)
por: Andree, Kiki C., et al.
Publicado: (2018) -
Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I–II early‐stage melanoma
por: Ortega‐Martínez, Idoia, et al.
Publicado: (2016) -
Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma
por: Strijker, Marin, et al.
Publicado: (2019) -
Predictive value of chromosome 18q11.2‐q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III‐trial AGITG‐MAX
por: van Dijk, Erik, et al.
Publicado: (2022)